Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Jianjiao Ni, Guodong Li, Xi Yang, Li Chu, Jialei Wang, Yida Li, Liqing Zou, Yuan Li, Congying Xie, Zhengfei Zhu

ABSTRACT

BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown. METHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. RESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p = 0.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p = 0.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p = 0.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p = 0.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p = 0.048). CONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions. More... »

PAGES

44

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1

DOI

http://dx.doi.org/10.1186/s13014-019-1240-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112739159

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30866974


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ni", 
        "givenName": "Jianjiao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Guodong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Xi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chu", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Jialei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Yida", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zou", 
        "givenName": "Liqing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Yuan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Affiliated Hospital of Wenzhou Medical University", 
          "id": "https://www.grid.ac/institutes/grid.414906.e", 
          "name": [
            "Radiotherapy and Chemotherapy Department, the 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xie", 
        "givenName": "Congying", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Zhengfei", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.2016.9839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003526472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1408440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005474865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-12-0868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007331796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2014.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008009645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.59.0539", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016158843"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semcdb.2016.09.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016585125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016737978"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2013.11.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019077778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3111/13696998.2014.1003644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027632484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0000000000000648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029331288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1006448", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029333869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035605294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.prro.2016.05.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038999889"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.3312", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040085264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02841860802662722", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040375196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.62.0138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042043060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2014.12.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043860460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1214886", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046181766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3182745948", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047119041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep07268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047997157", 
          "https://doi.org/10.1038/srep07268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmct0806951", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050338991"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(17)30123-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074187710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079320625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.71.5904", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085191926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30339-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085964284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2017.395", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092730269", 
          "https://doi.org/10.1038/bjc.2017.395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2017.12.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099711099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2017.12.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099711099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103369506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3389/fonc.2018.00154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103883556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7150/jca.24950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103988345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.77.5841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104022577"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21492", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106916204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy405", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106933161"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown.\nMETHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2.\nRESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p\u2009=\u20090.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p\u2009=\u20090.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p\u2009=\u20090.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p\u2009=\u20090.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p\u2009=\u20090.048).\nCONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13014-019-1240-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1036451", 
        "issn": [
          "1748-717X"
        ], 
        "name": "Radiation Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses", 
    "pagination": "44", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b71775b5bfb19f6595306d6380c59c9381c201c46e861e0ef9b464d000d670b7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30866974"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101265111"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13014-019-1240-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112739159"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13014-019-1240-1", 
      "https://app.dimensions.ai/details/publication/pub.1112739159"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78970_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13014-019-1240-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'


 

This table displays all metadata directly associated to this object as RDF triples.

229 TRIPLES      21 PREDICATES      62 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13014-019-1240-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N6adec5c282d94f78985084b81e106930
4 schema:citation sg:pub.10.1038/bjc.2017.395
5 sg:pub.10.1038/srep07268
6 https://doi.org/10.1001/jama.2016.9839
7 https://doi.org/10.1016/j.ijrobp.2013.11.010
8 https://doi.org/10.1016/j.ijrobp.2014.12.010
9 https://doi.org/10.1016/j.jtho.2017.12.006
10 https://doi.org/10.1016/j.prro.2016.05.004
11 https://doi.org/10.1016/j.radonc.2014.12.009
12 https://doi.org/10.1016/j.semcdb.2016.09.016
13 https://doi.org/10.1016/s0140-6736(17)30123-x
14 https://doi.org/10.1016/s1470-2045(17)30339-x
15 https://doi.org/10.1056/nejmct0806951
16 https://doi.org/10.1056/nejmoa1006448
17 https://doi.org/10.1056/nejmoa1214886
18 https://doi.org/10.1056/nejmoa1408440
19 https://doi.org/10.1080/02841860802662722
20 https://doi.org/10.1093/annonc/mds124
21 https://doi.org/10.1093/annonc/mdt572
22 https://doi.org/10.1093/annonc/mdw305
23 https://doi.org/10.1093/annonc/mdy121
24 https://doi.org/10.1093/annonc/mdy405
25 https://doi.org/10.1097/jto.0000000000000648
26 https://doi.org/10.1097/jto.0b013e3182745948
27 https://doi.org/10.1158/1535-7163.mct-12-0868
28 https://doi.org/10.1200/jco.2007.15.3312
29 https://doi.org/10.1200/jco.2014.59.0539
30 https://doi.org/10.1200/jco.2015.62.0138
31 https://doi.org/10.1200/jco.2016.71.5904
32 https://doi.org/10.1200/jco.2017.77.5841
33 https://doi.org/10.3111/13696998.2014.1003644
34 https://doi.org/10.3322/caac.21492
35 https://doi.org/10.3389/fonc.2018.00154
36 https://doi.org/10.7150/jca.24950
37 schema:datePublished 2019-12
38 schema:datePublishedReg 2019-12-01
39 schema:description BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown. METHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. RESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p = 0.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p = 0.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p = 0.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p = 0.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p = 0.048). CONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree true
43 schema:isPartOf N6334e8ef440240898e31df9fbc311830
44 N89fbed86cf7b4cc488b6038883e61158
45 sg:journal.1036451
46 schema:name Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses
47 schema:pagination 44
48 schema:productId N33889f3776e748279c0c9bed6ed12660
49 N5856684b5cf04b009619719e75320e33
50 N8a8e60058c6d480ba6a19f4680b8883b
51 Nc74e3cdffc4048c0ae5cc4eb40b85e03
52 Nf1b9e8097277417b90c52844210a9a47
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112739159
54 https://doi.org/10.1186/s13014-019-1240-1
55 schema:sdDatePublished 2019-04-11T13:20
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N765c6273f40d4fd1970144e18d8afa75
58 schema:url https://link.springer.com/10.1186%2Fs13014-019-1240-1
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N0779757b539847c7bf60343e6eba3db6 rdf:first Nc4a29c9016f24a4b88865a3396c38dc7
63 rdf:rest N984d2aa4831a4f4c92ec9db09d859884
64 N24331465f35f489187d2ddc761b54325 rdf:first Nfd017daa6b53400687f5c4a9bf5e5109
65 rdf:rest Naefec90538d54ee9b99d5818436f4146
66 N25e60011cb3e430eab4b026e90309de6 rdf:first Nf6c8b8bdc0a848328d7ad91af956e78c
67 rdf:rest N5cf244fd551a4b558513583f0cc453bc
68 N33889f3776e748279c0c9bed6ed12660 schema:name doi
69 schema:value 10.1186/s13014-019-1240-1
70 rdf:type schema:PropertyValue
71 N42397956b6994afdbe61ae0d8e622e32 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
72 schema:familyName Zhu
73 schema:givenName Zhengfei
74 rdf:type schema:Person
75 N4c162125ecbc4bcd90743e2f1e0288e0 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
76 schema:familyName Yang
77 schema:givenName Xi
78 rdf:type schema:Person
79 N5501c6e79d64422fa19172c234f885d6 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
80 schema:familyName Li
81 schema:givenName Yuan
82 rdf:type schema:Person
83 N5856684b5cf04b009619719e75320e33 schema:name pubmed_id
84 schema:value 30866974
85 rdf:type schema:PropertyValue
86 N58c7aeafceba46c5b47258af253b8268 rdf:first N6bd001301f3e48d08d346e012aaa8b39
87 rdf:rest N24331465f35f489187d2ddc761b54325
88 N5cf244fd551a4b558513583f0cc453bc rdf:first Nad88c704fa124e3f8683dd479a29e97c
89 rdf:rest N58c7aeafceba46c5b47258af253b8268
90 N6334e8ef440240898e31df9fbc311830 schema:issueNumber 1
91 rdf:type schema:PublicationIssue
92 N6adec5c282d94f78985084b81e106930 rdf:first Nb72a06040e0b40638bef212727a51e93
93 rdf:rest Nbfe7afd29b524e61b86368c520515ba6
94 N6bd001301f3e48d08d346e012aaa8b39 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
95 schema:familyName Li
96 schema:givenName Yida
97 rdf:type schema:Person
98 N71847504eda74f338be682290fde177a rdf:first N4c162125ecbc4bcd90743e2f1e0288e0
99 rdf:rest N25e60011cb3e430eab4b026e90309de6
100 N71fcf26eac8247af94edba496aa9edab schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
101 schema:familyName Li
102 schema:givenName Guodong
103 rdf:type schema:Person
104 N765c6273f40d4fd1970144e18d8afa75 schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 N89fbed86cf7b4cc488b6038883e61158 schema:volumeNumber 14
107 rdf:type schema:PublicationVolume
108 N8a8e60058c6d480ba6a19f4680b8883b schema:name readcube_id
109 schema:value b71775b5bfb19f6595306d6380c59c9381c201c46e861e0ef9b464d000d670b7
110 rdf:type schema:PropertyValue
111 N984d2aa4831a4f4c92ec9db09d859884 rdf:first N42397956b6994afdbe61ae0d8e622e32
112 rdf:rest rdf:nil
113 Nad88c704fa124e3f8683dd479a29e97c schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
114 schema:familyName Wang
115 schema:givenName Jialei
116 rdf:type schema:Person
117 Naefec90538d54ee9b99d5818436f4146 rdf:first N5501c6e79d64422fa19172c234f885d6
118 rdf:rest N0779757b539847c7bf60343e6eba3db6
119 Nb72a06040e0b40638bef212727a51e93 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
120 schema:familyName Ni
121 schema:givenName Jianjiao
122 rdf:type schema:Person
123 Nbfe7afd29b524e61b86368c520515ba6 rdf:first N71fcf26eac8247af94edba496aa9edab
124 rdf:rest N71847504eda74f338be682290fde177a
125 Nc4a29c9016f24a4b88865a3396c38dc7 schema:affiliation https://www.grid.ac/institutes/grid.414906.e
126 schema:familyName Xie
127 schema:givenName Congying
128 rdf:type schema:Person
129 Nc74e3cdffc4048c0ae5cc4eb40b85e03 schema:name nlm_unique_id
130 schema:value 101265111
131 rdf:type schema:PropertyValue
132 Nf1b9e8097277417b90c52844210a9a47 schema:name dimensions_id
133 schema:value pub.1112739159
134 rdf:type schema:PropertyValue
135 Nf6c8b8bdc0a848328d7ad91af956e78c schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
136 schema:familyName Chu
137 schema:givenName Li
138 rdf:type schema:Person
139 Nfd017daa6b53400687f5c4a9bf5e5109 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
140 schema:familyName Zou
141 schema:givenName Liqing
142 rdf:type schema:Person
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
147 schema:name Oncology and Carcinogenesis
148 rdf:type schema:DefinedTerm
149 sg:journal.1036451 schema:issn 1748-717X
150 schema:name Radiation Oncology
151 rdf:type schema:Periodical
152 sg:pub.10.1038/bjc.2017.395 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092730269
153 https://doi.org/10.1038/bjc.2017.395
154 rdf:type schema:CreativeWork
155 sg:pub.10.1038/srep07268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047997157
156 https://doi.org/10.1038/srep07268
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1001/jama.2016.9839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003526472
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/j.ijrobp.2013.11.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019077778
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/j.ijrobp.2014.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008009645
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1016/j.jtho.2017.12.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099711099
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.prro.2016.05.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038999889
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.radonc.2014.12.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043860460
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.semcdb.2016.09.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016585125
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/s0140-6736(17)30123-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1074187710
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s1470-2045(17)30339-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1085964284
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1056/nejmct0806951 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050338991
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1056/nejmoa1006448 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029333869
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1056/nejmoa1214886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046181766
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1056/nejmoa1408440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005474865
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1080/02841860802662722 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040375196
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1093/annonc/mds124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035605294
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1093/annonc/mdt572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016737978
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1093/annonc/mdw305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079320625
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1093/annonc/mdy121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103369506
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1093/annonc/mdy405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106933161
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1097/jto.0000000000000648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029331288
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1097/jto.0b013e3182745948 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047119041
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1158/1535-7163.mct-12-0868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007331796
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1200/jco.2007.15.3312 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040085264
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1200/jco.2014.59.0539 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016158843
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1200/jco.2015.62.0138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042043060
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1200/jco.2016.71.5904 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085191926
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1200/jco.2017.77.5841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104022577
211 rdf:type schema:CreativeWork
212 https://doi.org/10.3111/13696998.2014.1003644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027632484
213 rdf:type schema:CreativeWork
214 https://doi.org/10.3322/caac.21492 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106916204
215 rdf:type schema:CreativeWork
216 https://doi.org/10.3389/fonc.2018.00154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103883556
217 rdf:type schema:CreativeWork
218 https://doi.org/10.7150/jca.24950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103988345
219 rdf:type schema:CreativeWork
220 https://www.grid.ac/institutes/grid.11841.3d schema:alternateName Shanghai Medical College of Fudan University
221 schema:name Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China
222 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
223 Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China
224 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
225 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.414906.e schema:alternateName First Affiliated Hospital of Wenzhou Medical University
228 schema:name Radiotherapy and Chemotherapy Department, the 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
229 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...